376 related articles for article (PubMed ID: 31345778)
1. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S; Schattenberg JM; Demir M; Wiegand J; Geier A; Teuber G; Hofmann WP; Kremer AE; Spreda F; Kluwe J; Petersen J; Boettler T; Rainer F; Halilbasic E; Greinwald R; Pröls M; Manns MP; Fickert P; Trauner M;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):781-793. PubMed ID: 31345778
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial.
Haal S; Guman MSS; Boerlage TCC; Acherman YIZ; de Brauw LM; Bruin S; de Castro SMM; van Hooft JE; van de Laar AWJM; Moes DE; Schouten M; Schouten R; van Soest EJ; van Veen RN; de Vries CEE; Fockens P; Dijkgraaf MGW; Gerdes VEA; Voermans RP
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):993-1001. PubMed ID: 34715031
[TBL] [Abstract][Full Text] [Related]
3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
4. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
[TBL] [Abstract][Full Text] [Related]
5. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T; Imajo K; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):996-1007. PubMed ID: 32805205
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
Stefan N; Ramsauer M; Jordan P; Nowotny B; Kantartzis K; Machann J; Hwang JH; Nowotny P; Kahl S; Harreiter J; Hornemann S; Sanyal AJ; Stewart PM; Pfeiffer AF; Kautzky-Willer A; Roden M; Häring HU; Fürst-Recktenwald S
Lancet Diabetes Endocrinol; 2014 May; 2(5):406-16. PubMed ID: 24795254
[TBL] [Abstract][Full Text] [Related]
7. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
[TBL] [Abstract][Full Text] [Related]
8. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
9. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
Chappell LC; Bell JL; Smith A; Linsell L; Juszczak E; Dixon PH; Chambers J; Hunter R; Dorling J; Williamson C; Thornton JG;
Lancet; 2019 Sep; 394(10201):849-860. PubMed ID: 31378395
[TBL] [Abstract][Full Text] [Related]
11. Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled trial.
Vasikasin V; Rojdumrongrattana T; Chuerboonchai W; Siriwiwattana T; Thongtaeparak W; Niyasom S; Lertliewtrakool N; Jitsiri S; Changpradub D
Lancet Glob Health; 2019 May; 7(5):e664-e670. PubMed ID: 31000133
[TBL] [Abstract][Full Text] [Related]
12. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
[TBL] [Abstract][Full Text] [Related]
14. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
[TBL] [Abstract][Full Text] [Related]
15. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ; Gaunt P; Aithal GP; Barton D; Hull D; Parker R; Hazlehurst JM; Guo K; ; Abouda G; Aldersley MA; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN
Lancet; 2016 Feb; 387(10019):679-690. PubMed ID: 26608256
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
